Published in J Immunol Methods on January 28, 1983
Gamma interferon activates human macrophages to become tumoricidal and leishmanicidal but enhances replication of macrophage-associated mycobacteria. Infect Immun (1985) 4.56
Activated murine macrophages secrete a metabolite of arginine with the bioactivity of endothelium-derived relaxing factor and the chemical reactivity of nitric oxide. J Exp Med (1989) 2.99
Decreased production of interferon-gamma by human neonatal cells. Intrinsic and regulatory deficiencies. J Clin Invest (1986) 2.05
Fate of Listeria monocytogenes in murine macrophages: evidence for simultaneous killing and survival of intracellular bacteria. Infect Immun (1994) 2.04
Implication of phagosome-lysosome fusion in restriction of Mycobacterium avium growth in bone marrow macrophages from genetically resistant mice. Infect Immun (1993) 1.98
Interaction of Mycobacterium avium complex with human macrophages: roles of membrane receptors and serum proteins. Infect Immun (1991) 1.97
Recombinant granulocyte/macrophage colony-stimulating factor activates macrophages to inhibit Trypanosoma cruzi and release hydrogen peroxide. Comparison with interferon gamma. J Exp Med (1987) 1.85
Inhibition of Ca(2+) signaling by Mycobacterium tuberculosis is associated with reduced phagosome-lysosome fusion and increased survival within human macrophages. J Exp Med (2000) 1.83
Inhibition of tumor cell ribonucleotide reductase by macrophage-derived nitric oxide. J Exp Med (1991) 1.83
Macrophage plasma membrane and secretory properties in murine malaria. Effects of Plasmodium yoelii blood-stage infection on macrophages in liver, spleen, and blood. J Exp Med (1986) 1.69
Activities of amikacin, roxithromycin, and azithromycin alone or in combination with tumor necrosis factor against Mycobacterium avium complex. Antimicrob Agents Chemother (1988) 1.54
Resistance to nitric oxide in Mycobacterium avium complex and its implication in pathogenesis. Infect Immun (1993) 1.53
Recombinant tumour necrosis factor-alpha decreases whereas recombinant interleukin-6 increases growth of a virulent strain of Mycobacterium avium in human macrophages. Immunology (1990) 1.51
Role of mononuclear phagocytes in expression of resistance and susceptibility to Mycobacterium avium infections in mice. Infect Immun (1986) 1.49
Interleukin-6 antagonizes tumor necrosis factor-mediated mycobacteriostatic and mycobactericidal activities in macrophages. Infect Immun (1992) 1.42
In vitro differentiation of human macrophages with enhanced antimycobacterial activity. J Clin Invest (2011) 1.29
Administration of recombinant interferon gamma to cancer patients enhances monocyte secretion of hydrogen peroxide. Proc Natl Acad Sci U S A (1985) 1.29
Hydrogen peroxide release by alveolar macrophages from sarcoid patients and by alveolar macrophages from normals after exposure to recombinant interferons alpha A, beta, and gamma and 1,25-dihydroxyvitamin D3. J Clin Invest (1987) 1.28
Idiopathic production of interleukin-1 in acquired immune deficiency syndrome. J Clin Microbiol (1987) 1.26
NOD2 controls the nature of the inflammatory response and subsequent fate of Mycobacterium tuberculosis and M. bovis BCG in human macrophages. Cell Microbiol (2010) 1.24
Characterization and growth in human macrophages of Mycobacterium avium complex strains isolated from the blood of patients with acquired immunodeficiency syndrome. Infect Immun (1990) 1.18
Localization of major histocompatibility complex class II molecules in phagolysosomes of murine macrophages infected with Leishmania amazonensis. Infect Immun (1991) 1.15
Production of TNF-alpha, IL-6 and TGF-beta, and expression of receptors for TNF-alpha and IL-6, during murine Mycobacterium avium infection. Immunology (1995) 1.14
Growth of Mycobacterium avium in activated macrophages harvested from inbred mice with differing innate susceptibilities to mycobacterial infection. Infect Immun (1988) 1.13
Effects of gamma interferon and nitric oxide on the interaction of Mycobacterium avium subsp. paratuberculosis with bovine monocytes. Infect Immun (1997) 1.11
The immune response to the cell wall of Mycobacterium bovis BCG. Clin Exp Immunol (1988) 1.11
Interleukin-12-stimulated natural killer cells can activate human macrophages to inhibit growth of Mycobacterium avium. Infect Immun (1995) 1.06
Interleukin-10 stimulates Coxiella burnetii replication in human monocytes through tumor necrosis factor down-modulation: role in microbicidal defect of Q fever. Infect Immun (2001) 1.06
The phagosomal environment protects virulent Mycobacterium avium from killing and destruction by clarithromycin. Infect Immun (1997) 1.00
Quantitative assessment of Fc receptor expression and function during in vitro differentiation of human monocytes to macrophages. Immunology (1986) 0.98
The tumor necrosis factor receptor and human neutrophil function. Deactivation and cross-deactivation of tumor necrosis factor-induced neutrophil responses by receptor down-regulation. J Clin Invest (1990) 0.98
T-cell-mediated immunity in persistent Mycobacterium intracellulare infections in mice. Infect Immun (1988) 0.96
Theiler's virus infection of primary cultures of bone marrow-derived monocytes/macrophages. J Virol (2002) 0.96
Preservation of monocyte effector functions against Mycobacterium avium-M. intracellulare in patients with AIDS. Infect Immun (1991) 0.96
Retracted Inhibition of growth of Mycobacterium avium in murine and human mononuclear phagocytes by migration inhibitory factor. Infect Immun (1993) 0.95
Response to stimulation with recombinant cytokines and synthesis of cytokines by murine intestinal macrophages infected with the Mycobacterium avium complex. Infect Immun (1995) 0.94
Activation of phospholipase D is tightly coupled to the phagocytosis of Mycobacterium tuberculosis or opsonized zymosan by human macrophages. J Exp Med (1996) 0.94
Inactivation of Mycobacterium tuberculosis mannosyltransferase pimB reduces the cell wall lipoarabinomannan and lipomannan content and increases the rate of bacterial-induced human macrophage cell death. Glycobiology (2009) 0.94
Pulmonary surfactant protein A and surfactant lipids upregulate IRAK-M, a negative regulator of TLR-mediated inflammation in human macrophages. Am J Physiol Lung Cell Mol Physiol (2012) 0.91
In vitro and ex vivo activities of antimicrobial agents used in combination with clarithromycin, with or without amikacin, against Mycobacterium avium. Antimicrob Agents Chemother (1995) 0.87
Recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) or tumour necrosis factor-alpha (TNF-alpha) activate human alveolar macrophages to inhibit growth of Mycobacterium avium complex. Clin Exp Immunol (1994) 0.87
Modulation of Mycobacterium lepraemurium growth in murine macrophages: beneficial effect of tumor necrosis factor alpha and granulocyte-macrophage colony-stimulating factor. Infect Immun (1991) 0.86
Suppression of immune response to Listeria monocytogenes: mechanism(s) of immune complex suppression. Infect Immun (1985) 0.85
Altered IL-1 expression and compartmentalization in monocytes from patients with AIDS stimulated with Mycobacterium avium complex. J Clin Immunol (1997) 0.82
Modulation of human monocyte Fc receptor function by surface-adsorbed IgG. Immunology (1987) 0.78
Mononuclear phagocytes: a major population of effector cells responsible for rejection of allografted tumor cells in mice. Proc Natl Acad Sci U S A (1991) 0.78
A study of Nigella sativa induced growth inhibition of MCF and HepG2 cell lines: An anti-neoplastic study along with its mechanism of action. Pharmacognosy Res (2015) 0.78
Diminished adherence and/or ingestion of virulent Mycobacterium tuberculosis by monocyte-derived macrophages from patients with tuberculosis. Clin Diagn Lab Immunol (1998) 0.76
Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J Immunol (1988) 14.21
Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med (1983) 14.08
Secretory products of macrophages. J Clin Invest (1987) 10.33
Alterations of macrophage functions by mediators from lymphocytes. J Exp Med (1971) 7.95
Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc Natl Acad Sci U S A (1997) 7.90
Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J Exp Med (1989) 7.72
Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res (1991) 6.99
Hydrogen peroxide release from mouse peritoneal macrophages: dependence on sequential activation and triggering. J Exp Med (1977) 5.44
Extracellular cytolysis by activated macrophages and granulocytes. II. Hydrogen peroxide as a mediator of cytotoxicity. J Exp Med (1979) 5.38
Macrophages secrete a novel heparin-binding protein with inflammatory and neutrophil chemokinetic properties. J Exp Med (1988) 5.16
Hydrogen peroxide metabolism in human monocytes during differentiation in vitro. J Clin Invest (1981) 4.46
The macrophage as an effector cell. N Engl J Med (1980) 4.30
Local and systemic effects of intradermal recombinant interferon-gamma in patients with lepromatous leprosy. N Engl J Med (1986) 4.05
Purification and characterization of the cytokine-induced macrophage nitric oxide synthase: an FAD- and FMN-containing flavoprotein. Proc Natl Acad Sci U S A (1991) 4.01
Characterization of a lymphocyte factor which alters macrophage functions. J Exp Med (1973) 3.98
Activation of mouse peritoneal macrophages in vitro and in vivo by interferon-gamma. J Immunol (1985) 3.85
Macrophage oxygen-dependent antimicrobial activity. II. The role of oxygen intermediates. J Exp Med (1979) 3.72
Extracellular cytolysis by activated macrophages and granulocytes. I. Pharmacologic triggering of effector cells and the release of hydrogen peroxide. J Exp Med (1979) 3.61
Macrophage deactivating factor and transforming growth factors-beta 1 -beta 2 and -beta 3 inhibit induction of macrophage nitrogen oxide synthesis by IFN-gamma. J Immunol (1990) 3.55
Gram-negative endotoxin: an extraordinary lipid with profound effects on eukaryotic signal transduction. FASEB J (1991) 3.41
Reduced biopterin as a cofactor in the generation of nitrogen oxides by murine macrophages. J Biol Chem (1989) 3.31
Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat Med (1998) 3.23
Activation of human macrophages. Comparison of other cytokines with interferon-gamma. J Exp Med (1984) 3.02
Activated murine macrophages secrete a metabolite of arginine with the bioactivity of endothelium-derived relaxing factor and the chemical reactivity of nitric oxide. J Exp Med (1989) 2.99
Suppression of arthritis by an inhibitor of nitric oxide synthase. J Exp Med (1993) 2.98
Antibiotic proteins of human polymorphonuclear leukocytes. Proc Natl Acad Sci U S A (1989) 2.59
Inhibition of macrophage and endothelial cell nitric oxide synthase by diphenyleneiodonium and its analogs. FASEB J (1991) 2.57
Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani. J Exp Med (1999) 2.51
A semi-automated micro-assay for H2O2 release by human blood monocytes and mouse peritoneal macrophages. J Immunol Methods (1985) 2.46
Experimental visceral leishmaniasis: production of interleukin 2 and interferon-gamma, tissue immune reaction, and response to treatment with interleukin 2 and interferon-gamma. J Immunol (1987) 2.45
N omega-hydroxy-L-arginine is an intermediate in the biosynthesis of nitric oxide from L-arginine. J Biol Chem (1991) 2.38
Liver macrophages in murine listeriosis. Cell-mediated immunity is correlated with an influx of macrophages capable of generating reactive oxygen intermediates. J Exp Med (1985) 2.37
Lymphokines enhance the capacity of human monocytes to secret reactive oxygen intermediates. J Clin Invest (1982) 2.23
Cellular responses to the intradermal injection of recombinant human gamma-interferon in lepromatous leprosy patients. Am J Pathol (1987) 2.18
International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer (2009) 2.13
High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene (2000) 2.04
Murine Kupffer cells. Mononuclear phagocytes deficient in the generation of reactive oxygen intermediates. J Exp Med (1985) 2.03
Mechanisms of macrophage antimicrobial activity. Trans R Soc Trop Med Hyg (1983) 2.01
Glutathione metabolism as a determinant of therapeutic efficacy: a review. Cancer Res (1984) 1.98
Essential role of induced nitric oxide in the initiation of the inflammatory response after hemorrhagic shock. J Exp Med (1998) 1.96
Shared actions of endotoxin and taxol on TNF receptors and TNF release. Science (1990) 1.91
Recombinant granulocyte/macrophage colony-stimulating factor activates macrophages to inhibit Trypanosoma cruzi and release hydrogen peroxide. Comparison with interferon gamma. J Exp Med (1987) 1.85
A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity. Cancer Res (1999) 1.85
Trace levels of bacterial lipopolysaccharide prevent interferon-gamma or tumor necrosis factor-alpha from enhancing mouse peritoneal macrophage respiratory burst capacity. J Immunol (1987) 1.85
Inhibition of tumor cell ribonucleotide reductase by macrophage-derived nitric oxide. J Exp Med (1991) 1.83
Secretion of oxygen intermediates: role in effector functions of activated macrophages. Fed Proc (1982) 1.81
Differential stimulation of murine lymphoma growth in vitro by normal and BCG-activated macrophages. J Exp Med (1975) 1.77
Characterization of the nonphagocytic adherent cell from the peritoneal cavity of normal and BCG-treated mice. J Immunol (1977) 1.77
Azurocidin and a homologous serine protease from neutrophils. Differential antimicrobial and proteolytic properties. J Clin Invest (1990) 1.74
Rapid interferon gamma-dependent clearance of influenza A virus and protection from consolidating pneumonitis in nitric oxide synthase 2-deficient mice. J Exp Med (1998) 1.74
Reactive nitrogen intermediates and the pathogenesis of Salmonella and mycobacteria. Curr Opin Microbiol (2000) 1.73
Tumor cell anti-oxidant defenses. Inhibition of the glutathione redox cycle enhances macrophage-mediated cytolysis. J Exp Med (1981) 1.71
L-citrulline production from L-arginine by macrophage nitric oxide synthase. The ureido oxygen derives from dioxygen. J Biol Chem (1990) 1.70
Phase I trial of recombinant interferon gamma in cancer patients. J Clin Oncol (1986) 1.68
Bmi1 is a MYCN target gene that regulates tumorigenesis through repression of KIF1Bbeta and TSLC1 in neuroblastoma. Oncogene (2010) 1.65
Congenital primitive neuroectodermal tumor with epithelial and glial differentiation. An ultrastructural and immunohistochemical study. Arch Pathol Lab Med (1990) 1.65
RIZ1, but not the alternative RIZ2 product of the same gene, is underexpressed in breast cancer, and forced RIZ1 expression causes G2-M cell cycle arrest and/or apoptosis. Cancer Res (1998) 1.62
Decreased phagocytosis by peritoneal macrophages from BCG-treated mice: induction of the phagocytic defect in normal macrophages with BCG in vitro. Cell Immunol (1977) 1.61
Secretion of pyruvate. An antioxidant defense of mammalian cells. J Exp Med (1987) 1.61
FAD and GSH participate in macrophage synthesis of nitric oxide. Biochem Biophys Res Commun (1990) 1.59
Suppression of macrophage oxidative metabolism by products of malignant and nonmalignant cells. J Exp Med (1982) 1.58
A new family of heparin-binding growth/differentiation factors: increased midkine expression in Wilms' tumor and other human carcinomas. Cancer Res (1993) 1.55
Enzymatic basis of macrophage activation. Kinetic analysis of superoxide production in lysates of resident and activated mouse peritoneal macrophages and granulocytes. J Biol Chem (1984) 1.54
Synthesis of nitrogen oxides from L-arginine by macrophage cytosol: requirement for inducible and constitutive components. Biochem Biophys Res Commun (1989) 1.53
Macrophage oxygen-dependent antimicrobial activity. IV. Role of endogenous scavengers of oxygen intermediates. J Exp Med (1980) 1.44
Functional channel formation associated with cytotoxic T-cell granules. Proc Natl Acad Sci U S A (1986) 1.43
Macrophages rapidly internalize their tumor necrosis factor receptors in response to bacterial lipopolysaccharide. J Biol Chem (1989) 1.42
Features and outcome of advanced neuroblastoma with distant lymph node metastasis. Pediatr Hematol Oncol (1992) 1.41
Antitumor effects of hydrogen peroxide in vivo. J Exp Med (1981) 1.41
Bacterial infection induces nitric oxide synthase in human neutrophils. J Clin Invest (1997) 1.40
Heat shock protein 90 mediates macrophage activation by Taxol and bacterial lipopolysaccharide. Proc Natl Acad Sci U S A (1999) 1.40
Mutation, allelotyping, and transcription analyses of the p73 gene in prostatic carcinoma. Cancer Res (1998) 1.39
Role of nitric oxide in antagonistic effects of transforming growth factor-beta and interleukin-1 beta on the beating rate of cultured cardiac myocytes. Mol Endocrinol (1992) 1.35
Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature. Oncogene (2007) 1.31
Glutathione depletion sensitizes tumor cells to oxidative cytolysis. J Biol Chem (1982) 1.31
p53 family genes: structural comparison, expression and mutation. Cell Death Differ (1999) 1.31
Downregulation of tumor necrosis factor receptors on macrophages and endothelial cells by microtubule depolymerizing agents. J Exp Med (1990) 1.29
Administration of recombinant interferon gamma to cancer patients enhances monocyte secretion of hydrogen peroxide. Proc Natl Acad Sci U S A (1985) 1.29
CD133 suppresses neuroblastoma cell differentiation via signal pathway modification. Oncogene (2010) 1.28
Hydrogen peroxide release by alveolar macrophages from sarcoid patients and by alveolar macrophages from normals after exposure to recombinant interferons alpha A, beta, and gamma and 1,25-dihydroxyvitamin D3. J Clin Invest (1987) 1.28
Resistance of human tumor cells in vitro to oxidative cytolysis. J Clin Invest (1985) 1.25
Neuroblastoma. Effect of genetic factors on prognosis and treatment. Cancer (1992) 1.23
p73 at chromosome 1p36.3 is lost in advanced stage neuroblastoma but its mutation is infrequent. Oncogene (1999) 1.22
Suppression of macrophage antimicrobial activity by a tumor cell product. J Immunol (1983) 1.19
Role of oxygen in T cell-mediated cytolysis. J Immunol (1982) 1.18
Isolation of a subpopulation of adherent peritoneal cells with anti-tumour activity. Nature (1976) 1.16
Lipopolysaccharide-related stimuli induce expression of the secretory leukocyte protease inhibitor, a macrophage-derived lipopolysaccharide inhibitor. Infect Immun (1998) 1.16
Increased susceptibility to tumorigenesis of ski-deficient heterozygous mice. Oncogene (2001) 1.14
New approach for detection of amplification in cancer DNA using restriction landmark genomic scanning. Cancer Res (1992) 1.11
p73, a gene related to p53, is not mutated in esophageal carcinomas. Int J Cancer (1998) 1.11
Expression of TrkA, TrkB and TrkC in human neuroblastomas. J Neurooncol (1997) 1.11
Identification of nitric oxide synthase 2 as an innate resistance locus against ectromelia virus infection. J Virol (1998) 1.10
Macrophage deactivation. Altered kinetic properties of superoxide-producing enzyme after exposure to tumor cell-conditioned medium. J Exp Med (1986) 1.10
Elevation of IL-18 in human sepsis. J Clin Immunol (2000) 1.09
Subcellular location and properties of bactericidal factors from human neutrophils. J Exp Med (1986) 1.09
Frequent deletions and mutations of the beta-catenin gene are associated with overexpression of cyclin D1 and fibronectin and poorly differentiated histology in childhood hepatoblastoma. Clin Cancer Res (2001) 1.09
Identification and characterization of a 500-kb homozygously deleted region at 1p36.2-p36.3 in a neuroblastoma cell line. Oncogene (2000) 1.09